Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

UK Authorities Fine GSK $54.4 Million

By Mike Botta | February 12, 2016

London – GlaxoSmithKline plc has been fined £37.6 million ($54.4 million) by the U.K.’s Competition and Markets Authority (CMA) for stalling the potential market entry of generic competitors to its Seroxat anti-depressant drug, also know as paroxetine.

Several other pharmaceutical companies also were fined for anti-competitive conduct and agreements in relation to the supply of paroxetine.

The CMA’s decision relates to conduct and agreements between 2001 and 2004 in which GlaxoSmithKline plc (GSK) agreed to make payments and other value transfers totaling more than  £50 million ($72.3 million) to suppliers of generic versions of the drug. The CMA found that the payments were aimed at delaying the potential entry of generic competitors into the UK market.

In 2001, several pharmaceutical companies—including Generics (UK) Limited and Alpharma Limited—were taking steps to enter the UK market for paroxetine with a generic version, according to CMA.

GSK challenged the pharmaceutical companies, alleging that their generic products would infringe its patents, and commenced litigation proceedings against Generics and Alpharma. Before that litigation went to trial, the pharmaceutical companies entered into agreements with GSK prohibiting their independent entry into the U.K. paroxetine market.

The U.K. authority found that the agreements with the two companies and with another company, identified as Norton Healthcare Limited, infringed the competition law prohibition on anti-competitive agreements and that GSK’s conduct in making such payments infringed the prohibition on abuse of a dominant position.

“Today’s decision sends out a strong message that we will tackle illegal behavior that is designed to stifle competition at the expense of customers, in this case, the (National Health Service) and, ultimately, taxpayers,” Michael Grenfell, the authority’s executive director for enforcement, said. “This investigation shows our determination to take enforcement action against illegal anti-competitive practices in sectors big and small.”

In all, the authorities leveled £45 million ($65.1 million) in fines connected to the matter.

GSK said it disagreed with the ruling and that the agreements were made to “settle costly, complex and uncertain patent disputes.” The company also said it is “considering its grounds for appeal.” GSK argued that the agreements allowed the companies to enter the marketplace early and ultimately enabled savings of £15 million ($21.7 million) for the National Health Service.

The fine leveled today is the largest since the British competition authority’s was formed in 2014. (Note: £1 = $1.45).

(Sources: Danica Kirka, Associated Press and U.K. Competition and Markets Authority)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE